Eli Lilly and Company (NYSE:LLY) Shares Set to Pay Quarterly Dividend of $1.73

Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend on Monday, October 26th. Stockholders of record on Friday, November 13th will be given a dividend of $1.73 per share on Thursday, December 10th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th.

Eli Lilly and Company has increased its dividend payment by an average of 0.2% per year over the last three years and has increased its dividend every year for the last 11 years. Eli Lilly and Company has a payout ratio of 23.3% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Eli Lilly and Company to earn $47.23 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 14.7%.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,279.29 on Tuesday. The stock has a market cap of $1.20 trillion, a P/E ratio of 42.93, a price-to-earnings-growth ratio of 1.71 and a beta of 0.46. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a 50 day moving average of $1,187.35 and a 200-day moving average of $1,086.38. Eli Lilly and Company has a 52 week low of $809.63 and a 52 week high of $1,321.21.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts expect that Eli Lilly and Company will post 33.22 EPS for the current fiscal year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A U.S. judge declined Novo Nordisk’s request to block Eli Lilly’s advertising for weight-loss medicines. The ruling allows Lilly to continue promoting its obesity-treatment portfolio and removes a potential legal and marketing setback. Eli Lilly defeats Novo Nordisk attempt to halt weight-loss drug ads
• Positive Sentiment: Bernstein raised its price target for LLY to $1,450 from $1,385, signaling increased confidence in Lilly’s earnings growth and obesity-drug opportunity. Bernstein Adjusts Price Target on Eli Lilly and Company
• Positive Sentiment: New clinical data strengthened Lilly’s pipeline case. Investigational olomorasib showed durable first-line activity in KRAS G12C-mutated lung cancer, while early data for sofe-m plus bevacizumab showed encouraging response and disease-control rates in ovarian cancer without major new safety signals. New data on Lilly’s investigational treatment olomorasib
• Positive Sentiment: Lilly declared a quarterly dividend of $1.73 per share, payable December 10 to shareholders of record November 13. Although the approximately 0.5% yield is modest, the payment reinforces shareholder returns and financial confidence. Lilly declares fourth-quarter 2026 dividend
• Neutral Sentiment: Investors are awaiting October 29 results. Lilly previously delivered $22.97 billion in quarterly revenue, up 47.7% year over year, and exceeded EPS expectations, but the stock’s elevated valuation means expectations for continued obesity-drug growth are high. Wall Street Has High Expectations for Eli Lilly Stock
• Negative Sentiment: Competition from Novo Nordisk, pricing pressure and concerns that revenue growth could moderate even as patient numbers increase remain risks. With LLY trading at a high earnings multiple, any earnings miss or cautious outlook could trigger volatility. Eli Lilly Stock Fell Ahead of Q3

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.